Public share offering in Faron — EUR 30.7 million

Carnegie acted as joint lead manager and bookrunner in Faron Pharmaceuticals’ share offering of 30,709,056 newly issued treasury shares and new shares.
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system.